Lamassu Pharma: Funding, Investors & Team (Nov 2026)
Lamassu Pharma is a biotech startup addressing the urgent medical requirement for severe acute pancreatitis. Their main product is a new small molecule treatment for this condition, originally created by top scientists at Mayo Clinic, showing promising results in preclinical studies to significantly reduce the mortality and suffering linked to severe acute pancreatitis. The company is now working on further testing to ensure its safety before moving on to clinical trials, with the overarching objective of saving the lives of those affected by this disease.
Lamassu Pharma has raised $2.7M across 1 funding round on record, the most recent an undisclosed round of $2.7M announced in Jun 2025.
That round is below the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lamassu Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Lamassu Pharma Funding Rounds
Lamassu Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Lamassu Pharma Funding Compared to Other Biotechnology Startups
Lamassu Pharma's latest round of $2.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lamassu Pharma in Biotechnology and Durham
Companies Similar to Lamassu Pharma
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Lamassu Pharma Funding FAQs
What does Lamassu Pharma do?
Lamassu Pharma is a biotech startup addressing the urgent medical requirement for severe acute pancreatitis. Their main product is a new small molecule treatment for this condition, originally created by top scientists at Mayo Clinic, showing promising results in preclinical studies to significantly reduce the mortality and suffering linked to severe acute pancreatitis. The company is now working on further testing to ensure its safety before moving on to clinical trials, with the overarching objective of saving the lives of those affected by this disease.
How much funding has Lamassu Pharma raised?
Lamassu Pharma has raised $2.7M across 1 round on record. The most recent is an undisclosed round of $2.7M announced in Jun 2025.
When did Lamassu Pharma last raise funding?
Lamassu Pharma's most recent funding round on record is an undisclosed round of $2.7M, announced in Jun 2025.
Who founded Lamassu Pharma?
FundedIQ lists Gabi Hanna (Founder) at Lamassu Pharma.
Where is Lamassu Pharma headquartered?
Lamassu Pharma is based in Durham, North Carolina, United States.
How many employees does Lamassu Pharma have?
Lamassu Pharma is in the 1-10 employee band.
How does Lamassu Pharma's funding compare to other Biotechnology startups?
Lamassu Pharma's latest round of $2.7M is below the $8.8M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Lamassu Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lamassu Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.